Commonwealth Equity Services, LLC 9 Meters Biopharma, Inc. Transaction History

Commonwealth Equity Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.21 - $0.32 $21,879 - $33,340	104,190 Added 35.88%	394,592 $84,000
Q2 2022 Jul 19, 2022	BUY	$0.26 - $0.64 $20,800 - $51,200	80,000 Added 38.02%	290,402 $75,000
Q1 2022 May 04, 2022	BUY	$0.52 - $1.0 $19,916 - $38,300	38,300 Added 22.25%	210,402 $126,000
Q4 2021 Jan 31, 2022	BUY	$0.85 - $1.33 $16,192 - $25,336	19,050 Added 12.45%	172,102 $168,000
Q3 2021 Oct 29, 2021	BUY	$1.03 - $1.41 $79,361 - $108,640	77,050 Added 101.38%	153,052 $198,000
Q2 2021 Aug 11, 2021	BUY	$1.04 - $1.5 $3,536 - $5,100	3,400 Added 4.68%	76,002 $83,000
Q1 2021 May 04, 2021	BUY	$0.84 - $2.16 $48,300 - $124,200	57,500 Added 380.74%	72,602 $84,000
Q4 2020 Feb 11, 2021	BUY	$0.65 - $1.11 $9,816 - $16,763	15,102 New	15,102 $12,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.